with a particular interest in respiratory tract infections. The guidelines presented in this paper are a representation of the opinions of these experts.
These guidelines were developed solely to help in the initial antimicrobial management of patients with community acquired pneumonia. They are neither definitive nor all encompassing but are meant solely to provide the practising physician with a rational approach to the initial treatment of community acquired pneumonia and are based upon careful consideration of etiological and epidemiological factors and, above all, the safety and welfare of the patient. Whenever possible, attempts should be made to establish a precise etiological diagnosis. In cases where a specific pathogen is identified, therapy may be specifically targeted using an antimicrobial with a relatively narrow spectrum of activity to which the organism is sensitive. In choosing any antimicrobial, once issues of efficacy and toxicity have been addressed, cost should then be considered.
In developing these guidelines, it was felt that to be workable they must be kept as practical and as simple as possible. Trying to encompass every eventuality would lead to overly complex guidelines that ultimately would be discarded. Accordingly, we have chosen not to deal with the issue of tuberculosis or with high risk patients, such as those with human immunodeficiency virus infection, neoplastic disease 'Due to the high mortality associated with P aeruginosa, an aminoglycoside should be added at least for the first few days, whether one uses a third generation cephalosporin, imipenem or ciprofloxacin. tFirst-line cover for S aureus (oxacilfin-sensitive) is a penicillinase-resistant semisynthetic penicillin; however, the regimens listed above, while not optimal, would provide reasonable cover until identification and sensitivities of the pathogens were determined, at which time therapy may be altered or immunosuppressed patients. Such patients generally tend to be managed by physicians with specific expertise in these areas. Since insufficient data exist on the true incidence of viral causes of community acquired pneumonia, we have excluded viruses from these guidelines.
APPROACH TO PNEUMONIA Although a variety of classifications of pneumonia exist, we have chosen to base our approach to treatment upon the following four variables:
• The severity of illness upon clinical presentation;
• Whether the pneumonia was acquired in the community setting itself or in a nursing home; • The presence or absence of comorbid illness ( or age older than 65 years); • Whether treatment is to be given in the community setting, the nursing home or following admission of the patient to a hospital. While an absolute definition of severity of illness is not possible, some general guidelines can be provided. Criteria for 'severe pneumonia' include patients presenting with any of the following: respiratory failure (Pa02<60 mmHg [with the exception of patients with chronic obstructive lung disease who may be hypoxemic without pneumonial); respiratory rate more than 30/min; sepsis with evidence of end organ dysfunction; extrapulmonary septic complications; cavitation or involvement of more than one lobe on chest radiograph (3) (4) (5) .
Comorbid illness is defined as chronic obstructive lung disease, diabetes mellitus, renal insufficiency, congestive heart failure or recent hospitalization within one year of the presentation with pneumonia (6) . Other medical conditions may also exist that might be construed as comorbid conditions. The attending physician's clinical judgement should be used in assessing such cases.
An approach which incorporates these factors allowed *If patient is to be transferred to hospital for treatment, see Table 2 consideration of the greatest number of variables that might impact upon the treatment as well as the prognosis of the individual patient. We specifically avoided the use of a syndrome approach since there can be considerable overlap in clinical symptoms and physical signs, especially in the elderly (7) . These guidelines presuppose that in all cases, the individual physician dealing with the patient is the best judge of what to do. In all cases, knowledge of local epidemiology and resistance patterns should be used to modify these guidelines where appropriate. Based upon the variables mentioned above, the various treatment options are presented in Tables 1, 2, 3 and 4. We have tried to use classes of drugs rather than individual agents whenever possible. However, if only one drug in a given class is available or felt to be suitable, then a specific drug name has been used. Tables I and 2 deal with patients who have acquired pneumonia in the community setting and who present with clinical pictures that are not severe and severe, respectivel y. Tables 3 and 4 For patients admitted to hospital, close follow-up is assured but for patients treated at home, follow-up at two to three days is important. In all cases, whenever additional information, such as culture and sensitivity data, which may impact treatment comes to light, the responsible physician should make any necessary modifications or adjustments to the initial treatment regimen.
There is no single approach to the diagnosis and treatment of pneumonia that will suffice under all circumstances. What we are using here is an approach that allows for the initial selection of empiric antimicrobial therapy.
While penicillin is the drug of choice for infection caused by sensitive strains of Streptococcus pneumoniae, it does not provide cover for pathogens such as Mycoplasma pneumoniae, Legionella pneumophila and Chlamydia pneumoniae. Erythromycin, which has excellent activity against the latter three pathogens, is essentially ineffective against Haemophilus influenzae. To confound the situation further, betalactamase production by H influenzae and Moraxella catarrhalis makes routine use of ampicillin or amoxicillin unwise (8) . Obviously, if a proper sputum sample shows many polymorphonuclear leukocytes and Gram-positive diplococci on Gram stain, penicillin would be the agent of choice. In many situations, however, the decisions are not as clear cut and it is for such situations that these guidelines are intended. As newer antimicrobials become available or as the epidemiology of responsible pathogens changes, these guidelines will be updated.
At present it is recommended that the diagnostic work-up of a patient with known or suspected pneumonia include a careful history, including identification of any comorbid conditions, and a thorough physical examjnation.
